

## Prostate cancer: Is the future focal?

Poster Session 57

Sunday, 26 March  
15:45 - 17:15

**Location:** Room Munich, North Hall (Level 1)

**Chairs:** E. Barret, Paris (FR)  
B. Hollenbeck, Ann Arbor (US)  
M. Valerio, Lausanne (CH)

### Aims and objectives of this session

The aim of this session is to update delegates on the use of focal therapy and non-whole gland treatments.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (\*) are 3 minutes in length, followed by 3 minutes for discussion.

- 758 **Intra-prostatic injection of PRX302 to focally ablate clinically significant prostate cancer: An open label, phase 2a study**  
By: [Shanmugabavan Y.](#)<sup>1</sup>, Bass E.<sup>1</sup>, Hulme A.<sup>2</sup>, Freeman A.<sup>3</sup>, Brew-Graves C.<sup>1</sup>, Potyka I.<sup>1</sup>, Ramachandran N.<sup>4</sup>, Emberton M.<sup>1</sup>, Ahmed H.U.<sup>1</sup>  
**Institutes:**<sup>1</sup>University College London, Division of Surgery and Interventional Sciences, London, United Kingdom, <sup>2</sup>Sophiris, Sophiris Bio Corporation, California, United States of America, <sup>3</sup>University College London Hospital, Dept. of Histopathology, London, United Kingdom, <sup>4</sup>University College London Hospital, Dept. of Radiology, London, United Kingdom
- 759 **Impact of the use of N2O for general anesthesia during high intensity focused ultrasound (HIFU) for the treatment of localized prostate cancer**  
By: [Potiron E.](#)<sup>1</sup>, Lacoste J.<sup>2</sup>, Le Goguic G.<sup>2</sup>, Rousseau T.<sup>2</sup>, Nevoux P.<sup>2</sup>  
**Institutes:**<sup>1</sup>Clinique Urologique Nantes Atlantis, Dept. of , Saint Herblain, France, <sup>2</sup>Clinique Urologique Nantes Atlantis, Dept. of, Saint Herblain, France
- 760 **Prospective comparative analysis of oncologic and functional outcomes between focal therapy and robotic radical prostatectomy**  
By: [Garcia Barreras S.](#)<sup>1</sup>, Sanchez-Salas R.<sup>1</sup>, Sivararam A.<sup>2</sup>, Secin F.<sup>3</sup>, Redondo C.<sup>1</sup>, Velilla G.<sup>1</sup>, Barret E.<sup>1</sup>, Nunes-Silva I.<sup>1</sup>, Srougi V.<sup>1</sup>, Baghdadi M.<sup>1</sup>, Galiano M.<sup>1</sup>, Rozet F.<sup>1</sup>, Cathala N.<sup>1</sup>, Mombet A.<sup>1</sup>, Prapotnich D.<sup>1</sup>, Cathelineau X.<sup>1</sup>  
**Institutes:**<sup>1</sup>Institut Mutualiste Montsouris, Dept. of Urology, Paris, France, <sup>2</sup>Memorial Sloan Kettering, Dept. of Urology, New York, United States of America, <sup>3</sup>CEMIC, Dept. of Urology, Buenos Aires, Argentina
- 761 **A phase III study comparing partial prostate ablation versus radical prostatectomy (PART) in intermediate risk prostate cancer – initial data from the feasibility study**  
By: [Leslie T.](#)<sup>1</sup>, Elliott D.<sup>3</sup>, Le Conte S.<sup>1</sup>, Brewster S.<sup>2</sup>, Sooriakumaran P.<sup>1</sup>, Bryant R.<sup>1</sup>, Dudderidge T.<sup>4</sup>, Rosario D.<sup>5</sup>, Catto J.<sup>5</sup>, Hindley R.<sup>6</sup>, Emberton M.<sup>7</sup>, Ahmed H.<sup>7</sup>, Donovan J.<sup>3</sup>, Hamdy F.<sup>1</sup>  
**Institutes:**<sup>1</sup>Oxford University - Churchill Hospital, Dept. of Urology, Oxford, United Kingdom, <sup>2</sup>Churchill Hospital, Dept. of Urology, Oxford, United Kingdom, <sup>3</sup>University of Bristol, Dept. of Social and Community Medicine, Bristol, United Kingdom, <sup>4</sup>University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom, <sup>5</sup>Sheffield Teaching Hospitals, Dept. of Urology, Sheffield, United Kingdom, <sup>6</sup>Basingstoke and North Hampshire Hospital, Dept. of Urology, Basingstoke, United Kingdom, <sup>7</sup>University College London Hospital, Dept. of Urology, London, United Kingdom
- 762 **First repeated biopsy represents the most informative predictor of progression-free survival at 3**

**years follow-up in patients included in an active surveillance protocol for low-risk prostate cancer**

**By:** Luzzago S.<sup>1</sup>, Suardi N.<sup>1</sup>, Dell'Oglio P.<sup>1</sup>, Fossati N.<sup>1</sup>, Capitanio U.<sup>1</sup>, Gandaglia G.<sup>1</sup>, Zaffuto E.<sup>1</sup>, Mirone V.<sup>2</sup>, Bertini R.<sup>1</sup>, Damiano R.<sup>4</sup>, Freschi M.<sup>3</sup>, Gaboardi F.<sup>1</sup>, Montorsi F.<sup>1</sup>, Briganti A.<sup>1</sup>

**Institutes:**<sup>1</sup>Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, <sup>2</sup>Federico II University, Dept. of Urology, Naples, Italy, <sup>3</sup>Vita-Salute University San Raffaele, Dept. of Pathology, Milan, Italy, <sup>4</sup>Magna Graecia University, Dept. of Urology, Catanzaro, Italy

763

**A nomogram for prediction of local cancer recurrence after primary prostate cryoablation**

**By:** El Shafei A.<sup>1</sup>, Tay K.J.<sup>2</sup>, Ross A.<sup>3</sup>, Given R.<sup>4</sup>, Parsons J.K.<sup>5</sup>, Mouraviev V.<sup>6</sup>, Polascik T.<sup>2</sup>, Jones J.S.<sup>1</sup>

**Institutes:**<sup>1</sup>Cleveland Clinic Foundation, Glickman Urological and Kidney Institute, Cleveland, United States of America, <sup>2</sup>Duke Cancer Institute, Dept. of Urology, Durham, United States of America, <sup>3</sup>The Johns Hopkins Medical Institution, Dept. of Urology, Baltimore, United States of America, <sup>4</sup>Eastern Virginia Medical School, Dept. of Urology, Virginia, United States of America, <sup>5</sup>UC San Diego Health System, Dept. of Urology, San Diego, United States of America, <sup>6</sup>Global Robotics Institute, Dept. of Urology, Celebration, United States of America

764

**MRI-guided transurethral ultrasound ablation in patients with localized prostate cancer: 24-month outcomes of a prospective phase I clinical trial**

**By:** Chin J.<sup>1</sup>, Relle J.<sup>2</sup>, Billia M.<sup>1</sup>, Siddiqui K.M.<sup>1</sup>, Kuru T.<sup>3</sup>, Hatiboglu G.<sup>3</sup>, Ionel V.P.<sup>3</sup>, Hafron J.<sup>2</sup>, Matthias R.<sup>3</sup>, Mueller-Wolf M.<sup>3</sup>, Zahra K.<sup>3</sup>, Kibria F.<sup>4</sup>, Burtnyk M.<sup>4</sup>, Schlemmer H-P.<sup>3</sup>, Pahernik S.<sup>3</sup>

**Institutes:**<sup>1</sup>Western University, Dept. of Urology, London, Canada, <sup>2</sup>Beaumont Health System, Department of Urology, Dept. of Urology and Radiology, Royal Oak, United States of America, <sup>3</sup>German Cancer Research Center (DKFZ), Dept. of Urology and Radiology, Heidelberg, Germany, <sup>4</sup>Profound Medical Inc., Dept. of Engineering, Toronto, Canada

765

**Withdrawn**

**By:**

**Institutes:**

766

**Neoadjuvant hormonal therapy for patients with low risk prostate cancer stimulates lymphvessel invasion and shorten biochemical recurrence-free survival periods**

**By:** Miyata Y.<sup>1</sup>, Mochizuki Y.<sup>1</sup>, Shida Y.<sup>1</sup>, Matsuo T.<sup>1</sup>, Hakariya T.<sup>1</sup>, Ohba K.<sup>1</sup>, Furusato B.<sup>2</sup>, Fukuoka J.<sup>2</sup>, Sakai H.<sup>1</sup>

**Institutes:**<sup>1</sup>Nagasaki University Graduate School of Biomedical Sciences, Dept. of Urology, Nagasaki, Japan, <sup>2</sup>Nagasaki University Hospital, Dept. of Pathology, Nagasaki, Japan

767

**Salvage prostate cryoablation in older men**

**By:** Parsons K.<sup>2</sup>, Ross A.<sup>3</sup>, El Shafei A.<sup>1</sup>, Hatem A.<sup>1</sup>, Cotta B.<sup>2</sup>, Tay K.J.<sup>4</sup>, Polascik T.<sup>4</sup>, Given R.<sup>5</sup>, Mouraviev V.<sup>6</sup>, Jones J.S.<sup>1</sup>

**Institutes:**<sup>1</sup>Cleveland Clinic Foundation, Glickman Urological and Kidney Institute, Cleveland, United States of America, <sup>2</sup>UC San Diego Health System, Dept. of Urology, San Diego, California, United States of America, <sup>3</sup>The Johns Hopkins Medical Institution, Dept. of Urology, Baltimore, United States of America, <sup>4</sup>Duke Cancer Institute, Dept. of Urology, Durham, United States of America, <sup>5</sup>Eastern Virginia Medical School, Dept. of Urology, Virginia, United States of America, <sup>6</sup>Global Robotics Institute, Dept. of Urology, Celebration, United States of America

\*768

**Current national trends in the management of locally advanced prostate cancer with radical therapies: Results from the English National Prostate Cancer Audit**

**By:** Sujenthiran A.<sup>1</sup>, Nossiter J.<sup>1</sup>, Charman S.<sup>1</sup>, Aggarwal A.<sup>1</sup>, Cathcart P.<sup>2</sup>, Payne H.<sup>3</sup>, Clarke N.<sup>4</sup>, Van Der Meulen J.<sup>1</sup>

**Institutes:**<sup>1</sup>Royal College of Surgeons, Clinical Effectiveness Unit, London, United Kingdom, <sup>2</sup>Guy's and St Thomas' NHS Foundation Trust, Dept. of Urology, London, United Kingdom, <sup>3</sup>University College London Hospitals, Dept. of Oncology, London, United Kingdom, <sup>4</sup>The Christie and Salford Royal NHS Foundation Trusts, Dept. of Urology, London, United Kingdom

V46

**MRI/US fusion office-based targeted cryoablation with local anesthesia**

**By:** Bianco F., Lozano-Kaplun S., Cedeno J., Barashi N., Scher J., Kaufman A., Lopez A., Nicholson M.

**Institutes:** Urological Research Network, Dept. of Urology, Miami Lakes, United States of America

17:00 - 17:07

**Summary**

E. Barret, Paris (FR)